[144] Corcept Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Corcept Therapeutics, Inc. (CORT) discloses a proposed sale of 2,200 common shares to be executed on 09/10/2025 through Fidelity Brokerage Services (NASDAQ). The filing lists an aggregate market value of $159,390 and reports 105,371,729 shares outstanding. The shares were acquired under an option granted 08/20/2018 and the reported payment method is cash. The filer, identified in past sales as Daniel Swisher, sold three prior blocks of 2,200 shares each on 06/10/2025, 07/10/2025 and 08/11/2025, with gross proceeds shown for each sale. Remarks and signature attestations are present but no additional explanatory text or plan-adoption date is provided.

Positive

• Disclosure compliance: The filing reports proposed sales and recent sales consistent with Rule 144 requirements
• Transaction detail provided: Broker, number of shares, aggregate market value, acquisition source (option granted 08/20/2018) and payment method (cash) are all listed

Negative

• Insider selling activity: The filer executed three prior sales of 2,200 shares each within the past three months and proposes another sale, indicating ongoing dispositions
• Context missing: No date is provided for any Rule 10b5-1 trading plan or additional explanation for the sales, limiting investor understanding of whether trades follow a pre-established plan

Insights

Securities Analyst

TL;DR Routine insider sale filing showing option-derived shares and multiple recent small disposals by the same insider.

The filing is procedural and complies with Rule 144 disclosure by reporting a proposed sale of 2,200 common shares to occur on 09/10/2025 via a registered broker with an aggregate market value of $159,390. The shares were obtained from an option granted in 2018 and will be paid in cash. Historical sales by the same individual are documented for the prior three months, each for 2,200 shares with stated gross proceeds. There is no additional financial performance, forward guidance, or corporate action described. The filing provides the necessary sale/acquisition chronology but does not include any explanatory context such as reasons for the sales or a 10b5-1 plan adoption date.

Corporate Governance Expert

TL;DR Disclosure meets form requirements but lacks contextual details on trading plan or material nonpublic information.

The notice documents an insider-originated transaction sequence and includes the standard attestation regarding material adverse information. It specifies acquisition via an option granted 08/20/2018 and a cash sale scheduled 09/10/2025, which suggests the sale arises from option exercise and subsequent disposition. The repeated small block sales over recent months are disclosed, enabling market transparency. The document does not state a plan adoption date for Rule 10b5-1 or additional remarks that would clarify whether sales follow a pre-existing trading plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2200	159390.00	105371729	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/10/2025	Option Granted - 08/20/2018	Issuer			2200	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel Swisher 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/10/2025	2200	155342.00
Daniel Swisher 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/10/2025	2200	156376.00
Daniel Swisher 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/11/2025	2200	159060.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 for CORT disclose?

The form discloses a proposed sale of 2,200 common shares on 09/10/2025 via Fidelity with an aggregate market value of $159,390 and notes acquisition from an option granted 08/20/2018.

Who is the seller named in the filing?

The filing identifies prior sales by Daniel Swisher and the proposed sale appears for the same account; no additional seller address or CIK details beyond the provided records are included.

Were there any recent sales by the same person?

Yes. The filer sold 2,200 shares on 06/10/2025, 07/10/2025, and 08/11/2025 with gross proceeds reported for each sale.

How were the shares acquired that are to be sold?

The shares were acquired via an option granted on 08/20/2018, and the filing reports payment for this sale as cash.

Does the filing state a Rule 10b5-1 trading plan adoption date?

No. The document does not provide a plan adoption date or indicate reliance on a Rule 10b5-1 plan.